Comunicato stampa

SELEZIONA PER DATA
Mar 2018

Sebia launches new-generation serum free light chain (sFLC) assays for multiple myeloma testing

New test assays improve analytics and clinical coherence for the diagnosis and monitoring of multiple myeloma

SCARICA PDF
Gen 2018

Sebia announces FDA clearance for its Hydrashift 2/4 daratumumab assay

The in vitro diagnostic test, developed in collaboration with Janssen, allows for assessment of response in patients with multiple myeloma by mitigating potential interference induced by daratumumab

SCARICA PDF
Gen 2017

Sebia signs agreement with Janssen Biotech to develop a multiple myeloma IVD test

Test allows for clear results of multiple myeloma patients’ response by eliminating potential interference induced by novel therapeutic antibody

SCARICA PDF
Giu 2016

Sebia and Abingdon Health sign exclusive global distribution agreement

Sebia will distribute worldwide Seralite®-FLC serum lateral flow immunoassays for the diagnosis and monitoring of multiple myeloma

SCARICA PDF
Mar 2016

Sebia HbA1c assay now has CE mark for diagnosis of diabetes

Sebia HbA1c assay now has CE mark for diagnosis of diabetes

SCARICA PDF
Giu 2015

Sebia brings to market new Capillarys 3 Tera with CE mark

Sebia brings to market new Capillarys 3 Tera automated system with CE mark HbA1c and serum protein testing, and immunotyping

SCARICA PDF
Lug 2014

Hemoglobins Atlas

This comprehensive new medical compendium commemorates ten years of Sebia’s excellence in the field of hemoglobin separation using capillary electrophoresis

SCARICA PDF
Nov 2011

New HbA1c diabetes diagnostic technology from Sebia

New HbA1c diabetes diagnostic technology from Sebia will help laboratories facing the fast changing environment of diabetes assessment

SCARICA PDF